ArticleHaematologica2016
Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.
Open access · goldAbstract readClinical Trial, Phase ILetterMulticenter Study
In one paragraph
Article in Haematologica, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 83 citations in OpenAlex.
- An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase Inhibitor.European journal of drug metabolism and pharmacokinetics · 2022Trial
- Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Blood · 2018Trial
- Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.Journal of clinical pharmacology · 2017Trial
- Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.The New England journal of medicine · 2016Trial
- Trial
- From development to clinical success: the journey of established and next-generation BTK inhibitors.Investigational new drugs · 2025Review
- Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice.International journal of molecular sciences · 2025Review
- Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors.Frontiers in pharmacology · 2025Review
- Recent Advancement in Drug Designing as Small Molecules in Targeted Cancer Therapy: Challenges and Future Directions.Current cancer drug targets · 2025Review
- Treatment of Double-Refractory Chronic Lymphocytic Leukemia-An Unmet Clinical Need.International journal of molecular sciences · 2024Review
- Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies.Scientific reports · 2023Article
- Reactive intermediates formation and bioactivation pathways of spebrutinib revealed by LC-MS/MS:Heliyon · 2023Article
- Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.Molecules (Basel, Switzerland) · 2023Review
- Review
- BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.Journal of hematology & oncology · 2022Review
- Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas.Cancers · 2022Review
- The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions.Cancers · 2022Review
- Article
- Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.Signal transduction and targeted therapy · 2021Review
- Prevention of Bone Destruction by Mechanical Loading Is Not Enhanced by the Bruton's Tyrosine Kinase Inhibitor CC-292 in Myeloma Bone Disease.International journal of molecular sciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 14 institutions in 1 country.
Jennifer R BrownDana-Farber Cancer Institute, Boston, MA, USA jennifer_brown@dfci.harvard.edu.
Wael A HarbHorizon Oncology Center, Lafayette, IN, USA.
Brian T HillDepartment of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, OH, USA.
Janice GabriloveTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jeff P SharmanWillamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA.
Marshall T SchreederClearview Cancer Institute, Huntsville, AL, USA.
Paul M BarrHematology/Oncology, University of Rochester Medical Center, Rochester, NY, USA.
James M ForanHematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Thomas P MillerUniversity of Arizona Cancer Center, Tucson, AZ, USA.
Jan A BurgerDepartment of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA.
Kevin R KellyUniversity of Texas Health Science Center at San Antonio, CTRC Institute for Drug Development, TX, USA.
Daruka MahadevanThe West Clinic, University of Tennessee Health Sciences Center, ACORN Research, LLC, Memphis, TN, USA.
Shuo MaRobert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Yan LiDepartment of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
Daniel W PierceDepartment of Translational Medicine, Celgene Corporation, San Francisco, CA, USA.
Evelyn BarnettCelgene Corporation, Summit, NJ, USA.
Jeffrey MarineCelgene Corporation, Summit, NJ, USA.
Monika MirandaCelgene Corporation, Summit, NJ, USA.
Ada AzaryanCelgene Corporation, Berkeley Heights, NJ, USA.
Xujie YuCelgene Corporation, Berkeley Heights, NJ, USA.
Pilar Nava-ParadaCelgene Corporation, Summit, NJ, USA.
Jay MeiCelgene Corporation, Summit, NJ, USA.
Thomas J KippsUniversity of California, San Diego, Moores Cancer Center, La Jolla, CA, USA.
Campbell Clinic · USClearview Cancer Institute · USCleveland Clinic · USDana-Farber Cancer Institute · USHorizon Oncology Center · USIcahn School of Medicine at Mount Sinai · USMayo Clinic in Florida · USNorthwestern University · USThe University of Texas Health Science Center at San Antonio · USThe University of Texas MD Anderson Cancer Center · USUniversity of Arizona Cancer CenterUniversity of California, San Diego · USUniversity of Rochester Medical Center · USWillamette Valley Cancer Institute and Research Center · US
Funding
Tumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LEONIDAS C. PLATANIAS · 1993 to 2026
$153.9MNCI NIH HHS P30 CA060553
Abstract
PubMed holds no abstract for this paper.
Indexed as
AcrylamidesAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overDisease-Free SurvivalFemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedProtein-Tyrosine KinasesPyrimidinesRecurrenceSurvival RateAcrylamidesAgammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein-Tyrosine KinasesPyrimidinesspebrutinibBTK inhibitorsCC-292chronic lymphocytic leukemiarefractoryrelapsedsingle-agentsmall lymphocytic lymphoma
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.